Parenteral Manual


Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Original Date: 
August 2005
Revised Date: 
September 2013
  • Rapid control of agitation in patients with schizophrenia and related psychotic disorders
Reconstitution and Stability: 
  • Reconstitute 10 mg vials with 2.1 mL of Sterile Water for Injection  for a concentration of 5 mg/mL
  • Reconstituted solution must be used within 1 hour of preparation, kept at room temperature

- Solutions Compatible: Sterile Water for Injection

- Additive/buretrol Compatible: no information

- Y-site Compatible: no information

- Incompatible: diazepam, haloperidol, lorazepam


(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

IM YES, inject slowly, deep into muscle
IV Direct NO
IV Intermittent Infusion NO
IV Continuous Infusion NO

(For neonatal dosages, refer to Neonatal IV Drug Manual.)


  • Safety and efficacy have not been studied


  • Initial: 10 mg IM.  Lower doses of 5 mg or 7.5 mg may be appropriate
  • Repeated doses: 5-10 mg IM 2 hours after the first injection and a third dose 4 hours after the second dose
  • Maximum: 20 mg/day (including olanzapine given orally); with no more than 3 injections in 24 hours


  • An initial dose of 5 mg IM should be given
Potential hazards of parenteral administration: 
  • Neuroleptic Malignant syndrome (hyperpyrexia, muscle rigidity, altered mental status, autonomic instability)
  • Somnolence, dizziness, weight gain
  • Orthostatic hypotension, syncope associated with bradycardia (infrequent)
  • Extrapyramidal symptoms are more likely with high doses
  • Hyperglycemia
  • Patients should be closely observed for 2-4 hours following injection for hypotension, bradyarrhythmia, and hypoventilation
  • Parenteral administration may be used for up to a maximum of 3 days
  • Should switch patient to oral therapy as soon as possible if ongoing therapy is required
  • Concomitant use of parenteral benzodiazepine is no recommended with IM OLANZapine

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.